BNTX – BioNTech SE
Float Short %
2.08
Margin Of Safety %
Put/Call OI Ratio
0.49
EPS Next Q Diff
-1.89
EPS Last/This Y
-0.17
EPS This/Next Y
1.05
Price
118.49
Target Price
143.56
Analyst Recom
1.36
Performance Q
10.83
Relative Volume
1.53
Beta
1.47
Ticker: BNTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | BNTX | 94.51 | 0.84 | 1.39 | 40394 |
| 2025-12-29 | BNTX | 95.21 | 0.84 | 0.44 | 40590 |
| 2025-12-30 | BNTX | 95.19 | 0.84 | 1.97 | 40707 |
| 2025-12-31 | BNTX | 95.19 | 0.84 | 0.64 | 41123 |
| 2026-01-02 | BNTX | 96.64 | 0.84 | 0.26 | 41142 |
| 2026-01-05 | BNTX | 96.87 | 0.84 | 4.42 | 41663 |
| 2026-01-06 | BNTX | 98.05 | 0.85 | 0.20 | 41807 |
| 2026-01-07 | BNTX | 100.08 | 0.83 | 0.17 | 42766 |
| 2026-01-08 | BNTX | 98.9 | 0.77 | 1.16 | 45527 |
| 2026-01-09 | BNTX | 99.93 | 0.76 | 0.68 | 45548 |
| 2026-01-12 | BNTX | 102.25 | 0.76 | 0.67 | 45618 |
| 2026-01-13 | BNTX | 107.18 | 0.76 | 0.25 | 46070 |
| 2026-01-14 | BNTX | 109.12 | 0.70 | 0.82 | 50448 |
| 2026-01-15 | BNTX | 106.12 | 0.72 | 0.74 | 52126 |
| 2026-01-16 | BNTX | 109 | 0.71 | 0.24 | 52524 |
| 2026-01-20 | BNTX | 105.57 | 0.51 | 0.37 | 31404 |
| 2026-01-21 | BNTX | 117.99 | 0.51 | 0.25 | 31973 |
| 2026-01-22 | BNTX | 118.39 | 0.49 | 0.17 | 33759 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | BNTX | 94.51 | -105.5 | -923.3 | -3.42 |
| 2025-12-29 | BNTX | 95.21 | -105.5 | -983.5 | -3.42 |
| 2025-12-30 | BNTX | 95.23 | -105.5 | -932.8 | -3.42 |
| 2025-12-31 | BNTX | 95.19 | -105.5 | -928.1 | -3.42 |
| 2026-01-02 | BNTX | 96.68 | -105.5 | -994.1 | -3.42 |
| 2026-01-05 | BNTX | 96.87 | -105.5 | -942.8 | -3.42 |
| 2026-01-06 | BNTX | 98.07 | -105.5 | -815.0 | -3.42 |
| 2026-01-07 | BNTX | 100.06 | -105.5 | -1007.1 | -3.42 |
| 2026-01-08 | BNTX | 98.82 | -105.5 | -883.3 | -3.42 |
| 2026-01-09 | BNTX | 99.90 | -105.5 | -971.8 | -3.42 |
| 2026-01-12 | BNTX | 102.22 | -105.5 | -1013.3 | -3.42 |
| 2026-01-13 | BNTX | 107.18 | -105.5 | -1097.4 | -3.42 |
| 2026-01-14 | BNTX | 109.11 | -105.5 | -995.9 | -3.42 |
| 2026-01-15 | BNTX | 106.08 | -105.5 | -852.0 | -3.42 |
| 2026-01-16 | BNTX | 109.01 | -105.5 | -1023.3 | -3.42 |
| 2026-01-20 | BNTX | 105.57 | -105.5 | -835.0 | -3.42 |
| 2026-01-21 | BNTX | 118.00 | -105.5 | -1305.7 | -3.42 |
| 2026-01-22 | BNTX | 118.49 | -105.5 | -955.4 | -3.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | BNTX | 0.00 | -2.33 | 2.37 |
| 2025-12-29 | BNTX | 0.00 | -2.33 | 2.37 |
| 2025-12-30 | BNTX | 0.00 | -2.33 | 2.37 |
| 2025-12-31 | BNTX | 0.00 | -2.33 | 2.37 |
| 2026-01-02 | BNTX | 0.00 | -2.33 | 2.37 |
| 2026-01-05 | BNTX | 0.00 | -2.34 | 2.37 |
| 2026-01-06 | BNTX | 0.00 | -2.34 | 2.37 |
| 2026-01-07 | BNTX | 0.00 | -2.34 | 2.37 |
| 2026-01-08 | BNTX | 0.00 | -2.34 | 2.37 |
| 2026-01-09 | BNTX | 0.00 | -2.34 | 2.37 |
| 2026-01-12 | BNTX | 0.00 | -2.17 | 2.37 |
| 2026-01-13 | BNTX | 0.00 | -2.17 | 2.08 |
| 2026-01-14 | BNTX | 0.00 | -2.17 | 2.08 |
| 2026-01-15 | BNTX | 0.00 | -2.17 | 2.08 |
| 2026-01-16 | BNTX | 0.00 | -2.17 | 2.08 |
| 2026-01-20 | BNTX | 0.00 | -1.88 | 2.08 |
| 2026-01-21 | BNTX | 0.00 | -1.88 | 2.08 |
| 2026-01-22 | BNTX | 0.00 | -1.88 | 2.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-2.03
Insider Transactions
Institutional Transactions
-1.88
Beta
1.47
Average Sales Estimate Current Quarter
823
Average Sales Estimate Next Quarter
215
Fair Value
Quality Score
56
Growth Score
35
Sentiment Score
72
Actual DrawDown %
74.5
Max Drawdown 5-Year %
-82.2
Target Price
143.56
P/E
Forward P/E
PEG
P/S
8.06
P/B
1.31
P/Free Cash Flow
EPS
-2.63
Average EPS Est. Cur. Y
-3.42
EPS Next Y. (Est.)
-2.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-17.92
Relative Volume
1.53
Return on Equity vs Sector %
-30.3
Return on Equity vs Industry %
-14.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.19
EBIT Estimation
-955.4
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading